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doi:10.1016/j.kjms.2011.06.029Abstract The purpose of this study was to investigate the potential risk factors for the
reactivation of the replication of hepatitis B virus (HBV) and hepatitis C virus (HCV) after
transcatheter arterial chemoembolization (TACE) of hepatocellular carcinoma. Forty-four
hepatocellular carcinoma patients treated by TACE using epirubicin plus mitomycin C were
studied. Serum HBV DNA (nZ 17) and HCV RNA (nZ 27) levels were measured 1 day before
and 3 months after TACE. Plasma concentrations of chemotherapeutic agents were determined
at 1 hour and 72 hours after TACE. A total of 29 patients (nZ 13 for chronic hepatitis Band
nZ 16 for chronic hepatitis C) showed significant changes of the viral loads after TACE.
Patients with increased viral loads after TACE were older (pZ 0.041), had higher incidence
of pre-TACE white blood cell counts being less than normal limit (pZ 0.023), and had higher
plasma mitomycin C concentrations (pZ 0.039) than those in patients with decreased viral
loads. Analysis by multiple logistic regressions using age, decreased or normal pre-TACE white
blood cell counts, mitomycin C concentrations >3.95 ng/mL adopted by receiver operating
characteristic curve (pZ 0.037), and epirubicin concentrations have shown that decreasedepatobiliary Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, No.
aiwan.
om.tw (Z.-Y. Lin).
vier Taiwan LLC. All rights reserved.
Replication of HBV and HCV after TACE 555Table 1 Basic characteristics of
Items C
Sex (male/female)*
Age (y)*
Child-Pugh class (A/B)
HCC staging
I
II
IIIA
IIIC
IV
Data for continuous variables are ex
applied for statistical analysis. HCC
*p value< 0.05.
HCCZ hepatocellular carcinoma.pre-TACE white blood cell counts was the only significant factor associated with increased viral
loads after TACE (pZ 0.048). In conclusion, patients with decreased pre-TACE white blood cell
counts have a potential risk for the reactivation of the replication of HBV or HCV after TACE.
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.Introduction
Hepatocellular carcinoma (HCC) is the third most common
cause of cancer-related deaths worldwide [1]. Chronic
hepatitis B virus (HBV) and hepatitis C virus (HCV) infections
comprise the major etiologies in the development of HCC
[1,2]. Transcatheter arterial chemoembolization (TACE) is
one of the palliative treatments in the management of HCC
[2e5]. Our previous study showed that a high proportion of
HCC patients treated by TACE had detectable plasma
chemotherapeutic concentrations within 72 hours after the
procedure [6]. Reactivation of HBV or HCV is frequently
observed in patients after immunosuppressive therapy
[7e13]. However, influence of TACE on viral replication
remains controversial [14e17], which might partly be
attributed to differences in the study designs and selections
of patients and chemotherapeutic agents. The association
between the plasma concentrations of chemotherapeutic
agents and the reactivation of viral replication after TACE
has rarely been investigated. The purpose of this prospec-
tive study was to investigate the potential risk factors for
the reactivation of replication of HBV and HCV after TACE.
The concentrations of leaked chemotherapeutic agent
after TACE were added in the analysis.
Materials and methods
Patient selection
From February 2008 to February 2009, a total of 44
consecutive HBV- or HCV-infected HCC patients who plan-
ned to receive TACE and agreed to participate this study
were enrolled (Table 1). Patients who had been treated by
antiviral therapy for chronic hepatitis B (CHB) or chronic
hepatitis C (CHC) were excluded. None of patients receivedpatients
hronic hepatitis B (nZ 17)
15/2
56, 37e78
14/3
7
4
6
pressed as median and range. Th
staging is based on the Americanantiviral therapy during this study period. The diagnosis of
HCC was based on fine-needle aspiration cytology and/or
biopsy with positive findings on computed tomography and
angiography. HCC staging was based on the American Joint
Committee on Cancer TNM staging system [18]. Patients
with large arterioportal shunt, which needed to be treated
by implantation of various sizes of Nester Embolization
Coils (Cook Incorporated, Bloomington, IN, USA), were
excluded. Patients with chronic CHB or CHC were diagnosed
by seropositivity of hepatitis B surface antigen or anti-HCV
antibody for more than 6 months. Child-Pugh classification
was applied to evaluate the hepatic reserved function. The
study was approved by the ethics committees at the
participating hospital and was carried out according to
the guidelines of the International Conference on Harmo-
nization for Good Clinical Practice. All patients gave
written informed consent before enrollment.
Procedure of TACE
TACE was carried out by infusion of the mixture of
chemotherapeutic agents and lipiodol (Lipiodol Ultra-Fluid;
Guerbet, Aulnay-sous-Bois, France) into the lesion followed
by embolization of the supplying arteries using various sizes
of nonabsorbable Embosphere Microspheres (BioSphere
Medical, Inc, Rockland, MA, USA) or absorbable agents
(Avitene Microfibrillar Collagen Hemostat; MedChem Prod-
ucts, Inc, Woburn, MA, USA; or gelfoam particles 1e2 mm in
size; Pharmacia & Upjohn Company, Kalamazoo, MI, USA).
All patients received both epirubicin (Pharmacia & Upjohn
S.p.A, Milan, Italy) and mitomycin C (Kyowa Hakko Kogyo
Co, Ltd, Tokyo, Japan) as chemotherapeutic agents. The
doses of chemotherapeutic agents and the amount of lip-
iodol depended on the size of the tumor. The choice of
using nonabsorbable or absorbable embolic agent depended
on the sizes and the patterns of the supplying arteries.Chronic hepatitis C (nZ 27) Total (nZ 44)
16/11 31/13
70, 51e85 65, 37e85
24/3 38/6
7 14
15 19
3 9
1 1
1 1
e Mann-Whitney test, Fisher’s exact test, or Chi-square test was
Joint Committee on Cancer TNM staging system.
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the tumors were embolized followed by the confirmation of
immediate post-TACE angiography. The whole procedure
was carried out by an independent radiologist who was
blind to the study. Rapid recurrence of HCC was defined as
an increase of tumor size >1 cm and/or new development
of intrahepatic or metastatic nodule. None of the patients
received additional TACE within 3 months after TACE.
Quantitative determination of serum HBV DNA and
HCV RNA levels
Serum HBV DNA and HCV RNA levels were measured quan-
titatively 1 day before and 3 months after TACE. The serum
used for the study was collected immediately from the
peripheral veins of the patients and was stored at 20C for
further investigation. HBV DNA levels were measured by the
nucleic acid amplification test (COBAS AmpliPrep/COBAS
TaqMan HBV Test; Roche, Branchburg, NJ, USA). The
dynamic range was between 20 IU/mL and 1.1 108 IU/mL.
The HCV RNA levels were measured by real-time poly-
merase chain reaction assay (Abbott RealTime HCV; Abbott,
Des Plaines, IL, USA). The lowest detection limit was
30 IU/mL. All HBV DNA or HCV RNA measurements were
performed at the same time by the same operator using the
same viral assay. Twofold or more increases in serum HBV
DNA or HCV RNA levels after TACE were considered as
significant increases in viral load caused by TACE [16],
whereas decreasing of more than half of pre-TACE serum
HBV DNA or HCV RNA levels was considered as a significant
decrease of the viral loads. Serum HBV DNA and HCV RNA
levels were logarithmically transformed (log10) for statis-
tical analysis.
Determination of epirubicin and mitomycin C
concentrations in plasma
Plasma concentrations of epirubicin and mitomycin C were
measured at 1 hour and at 72 hours after TACE. Plasma
concentrations of epirubicin and mitomycin C were detec-
ted by high-performance liquid chromatography (HPLC)
system using Hitachi pump L-2130 and Hitachi UV-Vis
detector L-2420 (Hitachi High-Technologies Corporation,
Tokyo, Japan) with Waters Model 717 Plus HPLC autoinjector
(American Instrument Exchange, Inc, Haverhill, MA, USA).
The results were analyzed by Hitachi Model D-2000 chro-
matography Data Station software (Hitachi High-
Technologies Corporation, Tokyo, Japan). To prevent high
protein concentrations in samples affecting the HPLC
separation, liquid-liquid extraction was used for clean-up
and preconcentration of the plasma samples. The detection
limit for both epirubicin and mitomycin C was 2 ng/mL. The
coefficient of variation values for intra-assay (calculation
from five measurements) were 3.5% and 7.6% for epirubicin
and mitomycin C, respectively.
Statistical analysis
Data were analyzed using JMP 7.0 software (SAS Institute,
Cary, NC, USA). All data for continuous variables were
expressed as median and range. The Mann-Whitney test wasused to compare the difference between medians of
continuous variables. The Fisher’s exact test or Chi-square
test was used to compare proportions between groups.
Correlation analysis was investigated by the calculation of
a correlation coefficient (r). A receiver operating charac-
teristic curve was used to establish the cutoff level that
provided the maximal diagnostic accuracy. Multiple logistic
regressions were used for multivariate analysis. The
statistical significance was defined as p< 0.05.Results
There was no significant difference in baseline viral loads
between patients with HCC staging I and II (4.403,
2.712e7.511 vs. 5.318, 1.146e7.532, pZ 0.601, for CHB;
2.901, 1.465e4.419 vs. 2.909, 0.495e3.558, pZ 0.525, for
CHC), whereas the baseline HBV DNA viral loads (rZ 0.528,
pZ 0.029), but not HCV RNA viral loads (rZ0.022,
pZ 0.914), were significantly correlated with serum
alanine aminotransferase (ALT) levels before TACE. Simi-
larly, only HBV DNA viral loads (rZ 0.482, pZ 0.05), but
not HCV RNA viral loads (rZ 0.192, p Z 0.336), remained
to have a significant correlation with serum ALT levels 3
months after TACE.
A total of 29 patients (nZ 13 for CHB and nZ 16 for
CHC) showed significant changes of the viral loads after
TACE. Among them, 26 patients (89.7%) had detectable
chemotherapeutic agents within 72 hours after TACE. HBV
DNA levels were significantly increased in five (29.4%) and
decreased in eight (47.1%) patients, whereas HCV RNA
levels were significantly increased in eight (29.6%) and
decreased in eight (29.6%) patients. Changes of viral loads
after TACE did not significantly differ between CHB and
CHC patients (p> 0.1). CHB patients with increased HBV
DNA levels were older (pZ 0.045), had lower pre-TACE viral
loads (pZ 0.03), and had higher incidence of pre-TACE
white blood cell counts lower than the normal limit
(pZ 0.031) (Table 2). Patients with increased HBV or HCV
viral loads were older (71 years, 49e85 years vs. 57 years,
37e84 years, pZ 0.041); had a higher incidence of pre-
TACE white blood cell counts lower than the normal limit
(decreased/normal counts, 8/5 vs. 3/13, pZ 0.023); and
had higher plasma mitomycin C concentrations (5.1 ng/mL
vs. 2.1 ng/mL, pZ 0.039) (Fig. 1) than the patients with
decreased viral loads. There was no significant difference in
plasma epirubicin concentrations between patients with
increased and decreased viral loads after TACE (5.4 ng/mL,
0e28.6 ng/mL vs. 3.8 ng/mL, 0e65.8 ng/mL, pZ 0.86)
(Fig. 2). Multiple logistic regressions using age, decreased
or normal pre-TACE white blood cell counts, mitomycin C
concentrations >3.95 ng/mL selected by receiver operating
characteristic curve (pZ 0.037), and epirubicin concen-
trations have shown that decreased pre-TACE white blood
cell counts was the only significant item associated with
increased viral loads after TACE (pZ 0.048) (Table 3).
Seven patients showed increased ALT levels to >100 IU/L 3
months after TACE. Among them, only two patients (one
CHB and one CHC) had increased viral loads after TACE.
There was no significant association between increased
viral loads and increased ALT levels to >100 IU/L 3 months
after TACE (p> 0.05). Fifteen patients experienced rapid
Table 2 Characteristics of the 29 patients whose viral loads changed after TACE
Items HBV DNA levels HCV RNA levels
Increased (nZ 5) Decreased (nZ 8) Increased (nZ 8) Decreased (nZ 8)
Sex (male/female) 4/1 7/1 5/3 7/1
Age (y) 68*, 49e78 52*, 37e68 72, 51e85 63, 52e84
Child-Pugh class (A/B) 5/0 7/1 8/0 5/3
HCC staging
I 2 4 2 2
II 1 1 4 4
IIIA 2 3 1 1
IIIC 1
IV 1
Log10 baseline viral loads (IU/mL) 3.78**, 2.71e5.1 6.12**, 3.61e7.53 4.72, 3.5e6.01 6.08, 4.21e7.42
Pre-TACE white blood cell count
(decreased/normal)
4/1*** 1/7*** 4/4 2/6
Leaked plasma mitomycin
C concentration (ng/mL)
4.5, 0e15.7 1.3, 0e7.2 5.35, 0e9.4 2.1, 0e5.6
Leaked plasma epirubicin
concentration (ng/mL)
3.5, 0e18 1.8, 0e11.3 7.2, 0e28.6 7.84, 0e65.8
Data for continuous variables are expressed as median and range. The Mann-Whitney test, Fisher’s exact test, or Chi-square test was
applied for statistical analysis. HCC staging is based on the American Joint Committee on Cancer TNM staging system. The higher plasma
concentration of mitomycin C or epirubicin in two measurements was applied for analysis.
*p valueZ 0.045; **pZ 0.03; ***pZ 0.031.
HBVZ hepatitis B virus; HCCZ hepatocellular carcinoma; HCVZ hepatitis C virus; TACEZ transcatheter arterial chemoembolization.
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CHB and nZ 10 for CHC). There was no significant associ-
ation between rapid recurrence of HCC and increase of viral
loads (p> 0.05) (Table 4).
Discussion
Whether TACE can affect viral replication remains a source
of significant debate. A retrospective study performed byFigure 1. Plasma mitomycin C concentrations after trans-
catheter arterial chemoembolization. The higher plasma
concentration of mitomycin C in two measurements was
applied for analysis. C, increased viral loads after chemo-
embolization; :, decreased viral loads after chemo-
embolization. pZ 0.039 for total and p> 0.05 for HBV and HCV
(Mann-Whitney test). HBVZ hepatitis B virus; HCVZ hepatitis
C virus.Jang et al. [14] has reported that TACE could reactivate
HBV. However, further studies, including one retrospective
[15] and one prospective study [16], suggested that the risk
of HBV reactivation after TACE was low. Moreover, Xu et al.
[17] have shown that TACE could decrease HBV DNA levels
in patients with HCC, especially for those with high pre-
TACE HBV DNA levels. The cause of this discrepancy is not
clear. These controversial results were also noted in the
present study. HBV DNA and HCV RNA viral loads might
either increase or decrease after TACE. The present results
demonstrated that pre-TACE white blood cell count was theFigure 2. Plasma epirubicin concentrations after trans-
catheter arterial chemoembolization. The higher plasma
concentration of epirubicin in two measurements was applied
for analysis. C, Increased viral loads after chemo-
embolization; :, decreased viral loads after chemo-
embolization. p> 0.05 for total, HBV, and HCV (Mann-Whitney
test). HBVZ hepatitis B virus; HCVZ hepatitis C virus.
Table 3 Odds ratios for increased hepatitis B virus or hepatitis C virus viral loads after TACE, calculated by multiple logistic
regressions
Items Odds ratio p (likelihood ratio test)
Age (y) 1.075484 0.1369
Decreased pre-TACE white blood cell counts vs. normal counts 7.4440162 0.0479
Leaked mitomycin C concentrations >3.95 ng/mL vs. 3.95 ng/mL 3.2954142 0.265
Leaked epirubicin concentrations (ng/mL) 0.988408 0.7283
The higher plasma concentration of mitomycin C or epirubicin in two measurements was applied for analysis.
TACEZ transcatheter arterial chemoembolization.
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of HBV or HCV viral loads. This indicates that the status of
host defense is the major determinant for viral replication
after TACE. Although age and leaked mitomycin C concen-
trations were not statistically significant determinants for
the reactivation of viral replication after TACE determined
by multiple logistic regressions, these two factors might
still have a potential to affect the viral replication after
TACE. Aging is a potential unfavorable factor of immune
dysfunction because of impairment of T-cell production or
responsiveness [19,20]. Unlike epirubicin, which is less
myelotoxic [21], bone marrow suppression is the most
common and severe toxic side effect of mitomycin C [22].
Although the leaked plasma mitomycin C concentrations
were low in comparison with systemic chemotherapy, the
host immune status might also be suppressed by the leaked
mitomycin C. No statistical significance of age and leaked
mitomycin C as risk factors for the reactivation of viral
replication may be because of the small sample size of this
study.
Increase of HBV DNA viral loads can initiate host immune
response and also cause elevation of ALT levels [23,24].
HBV reactivation after chemotherapy or immunosuppres-
sive therapy might follow the two steps. First, immune
suppression results in viral replication. Second, restoration
of immune function after withdrawal of immune suppres-
sion causes immune-mediated destruction of HBV-infected
hepatocytes [25]. Although our results also showed weak
correlation between HBV DNA levels and ALT levels, there
was no significant association between increased viral loads
and increased ALT levels to >100 IU/L 3 months after TACE.
This result was in accordance with previous studies [15,16].
No significant reactivation of CHB in patients with increased
viral loads after TACE may partially be explained by theirTable 4 Association between rapid recurrence of hepatocellul
arterial chemoembolization
Items Recurrence (þ) (
Hepatitis B virus DNA levels
Increased/no change or decreased (n) 3/2*
Hepatitis C virus RNA levels
Increased/no change or decreased (n) 4/6**
The Fisher’s exact test was applied for statistical analysis.
*p valueZ 0.117; **pZ 0.316.inadequate host responses. This can be supported by the
fact that these patients had a higher incidence of pre-TACE
white blood cell counts lower than the normal limit. This
might also be one of the explanations for no significant
reactivation of CHC in patients with increased viral loads
after TACE.
HBV and HCV viral loads may fluctuate during the natural
course of infection, which was the result from the inter-
action between host defense and viruses. In the present
study, 15 patients did not show significant changes in their
viral loads after TACE based on our criteria. However, this
did not mean that the viral loads in these patients had
absolutely no change. Small variation in viral loads after
TACE may be because of either the natural course of CHB or
CHC or the influence of TACE. Analysis of their data may
cause bias. Therefore, the definition of the change of viral
loads in the present study was based on the previous study
[16] with stricter criteria that would lessen the bias.
Theoretically, the present study would be better to recruit
CHB or CHC patients with untreated HCC as a control group.
However, it is very difficult to select the same status of host
defense in both control and experimental groups. More-
over, it would be unethical to withdraw possible anticancer
therapy in CHB or CHC patients with HCC. Therefore,
definitive proof of the change of viral loads in HBV/HCV-
related HCC is unlikely to obtain from prospective
controlled trials.
In conclusion, patients with decreased pre-TACE white
blood cell counts have a potential risk of the reactivation of
the replication of HBV or HCV after TACE. Whether old age
and leaked mitomycin C concentration are associate
determinants for the reactivation of HBV and HCV replica-
tion after TACE needs further investigation with larger
sample size.ar carcinoma and increase of viral loads after transcatheter
nZ 15) Recurrence () (nZ 29) Total (nZ 44)
2/10* 5/12
4/13** 8/19
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